https://www.hastim.fr https://www.hastim.fr/mission-et-valeurs https://www.hastim.fr/immunotherapie-traitement-cancer https://www.hastim.fr/objectifs-5-ans https://www.hastim.fr/equipe https://www.hastim.fr/references-partenariats https://www.hastim.fr/publications https://www.hastim.fr/sante-animale https://www.hastim.fr/sante-animale/traitement-du-cancer https://www.hastim.fr/sante-animale/pathologies-traitees https://www.hastim.fr/sante-animale/nos-resultats https://www.hastim.fr/sante-animale/kit-apavac https://www.hastim.fr/veterinaires-partenaires https://www.hastim.fr/sante-humaine https://www.hastim.fr/sante-humaine/objectif-oncologie-humaine https://www.hastim.fr/sante-humaine/resultats-pre-cliniques https://www.hastim.fr/sante-humaine/vers-la-recherche-clinique https://www.hastim.fr/veterinaires/mot-de-passe-oublie https://www.hastim.fr/veterinaires/inscription https://www.hastim.fr/en https://www.hastim.fr/lexique https://www.hastim.fr/limmunotherapie-une-solution-au-coeur-de-linnovation-dans-les-traitements-contre-les-cancers https://www.hastim.fr/une-approche-one-health-une-seule-sante https://www.hastim.fr/contact https://www.hastim.fr/mentions-legales https://www.hastim.fr/en/mission-and-values https://www.hastim.fr/en/immunotherapy-and-cancer https://www.hastim.fr/immunotherapie-traitement-cancer/un-vaccin-therapeutique-autologue-contre-le-cancer https://www.hastim.fr/sante-animale/traitement-du-cancer-animal/limmunotherapie-pour-lutter-contre-le-cancer https://www.hastim.fr/en/5-year-targets https://www.hastim.fr/en/team https://www.hastim.fr/en/references-partnerships https://www.hastim.fr/en/publications https://www.hastim.fr/publications/hastim-articles https://www.hastim.fr/publications/sante-humaine https://www.hastim.fr/publications/sante-animale https://www.hastim.fr/publications/etude-de-cas https://www.hastim.fr/publications/newsletter https://www.hastim.fr/publication/cas-clinique-carcinome-intestinal-mucineux-canin-et-immunotherapie https://www.hastim.fr/publication/immunotherapie-apavac-integree-dans-une-strategie-multimodale-de-traitement-dun-osteosarcome-canin https://www.hastim.fr/publication/cas-clinique-efficacite-de-limmunotherapie-apavac-dans-le-traitement-adjuvant-dun-melanome-muqueux-canin https://www.hastim.fr/publication/les-3-cles-de-limmunotherapie-autologue-apavac-3-lhydroxyapatite https://www.hastim.fr/publication/les-3-cles-de-limmunotherapie-autologue-apavac-2-les-proteines-du-choc-thermique https://www.hastim.fr/publication/les-3-cles-de-limmunotherapie-autologue-apavac-1-les-antigenes-tumoraux https://www.hastim.fr/publication/vaccin-therapeutique-autologue-apavac-le-role-du-systeme-ganglionnaire https://www.hastim.fr/publication/vaccin-therapeutique-autologue-apavac-et-gene-tp53 https://www.hastim.fr/publication/etude-de-cas-melanome-equin https://www.hastim.fr/publication/vaccination-autologue-apavac-quelles-indications-pour-quels-animaux https://www.hastim.fr/publication/etude-de-cas-osteosarcome-canin https://www.hastim.fr/publication/comment-preparer-le-vaccin-autologue-anti-tumoral https://www.hastim.fr/en/animal-health https://www.hastim.fr/sante-animale/kit-apavac/les-atouts-du-traitement-apavac https://www.hastim.fr/sante-animale/kit-apavac/la-preparation-du-traitement-apavac https://www.hastim.fr/en/animal-health/cancer-treatment https://www.hastim.fr/en/animal-health/diseases-treated https://www.hastim.fr/sante-animale/pathologies-traitees/les-especes-concernees https://www.hastim.fr/sante-animale/pathologies-traitees/cancer-chez-les-animaux-de-compagnie https://www.hastim.fr/sante-animale/traitement-du-cancer-animal https://www.hastim.fr/en/animal-health/our-results https://www.hastim.fr/en/animal-health/apavac-kit https://www.hastim.fr/en/partner-veterinarians https://www.hastim.fr/en/human-health https://www.hastim.fr/limmunotherapie-une-solution-au-coeur-de-linnovation-dans-les-traitements-contre-les-cancers/notre-traitement-dimmunotherapie-un-vaccin-therapeutique-autologue https://www.hastim.fr/publication/transfection https://www.hastim.fr/en/human-health/human-oncology-objective https://www.hastim.fr/sante-humaine/objectif-oncologie-humaine/contexte-et-concept https://www.hastim.fr/sante-humaine/objectif-oncologie-humaine/premiers-resultats https://www.hastim.fr/sante-humaine/objectif-oncologie-humaine/notre-objectif https://www.hastim.fr/en/human-health/pre-clinical-results https://www.hastim.fr/en/human-health/toward-clinical-research https://www.hastim.fr/en/veterinarians/forgot-password https://www.hastim.fr/en/veterinarians/sign-up https://www.hastim.fr/en/glossary https://www.hastim.fr/en/low-environmental-impact-processing https://www.hastim.fr/en/contact https://www.hastim.fr/en/legal-notices https://www.hastim.fr/en/immunotherapy-and-cancer/our-immunotherapy-treatment-an-autologous-therapeutic-vaccine https://www.hastim.fr/en/animal-health/cancer-treatment/immunotherapy-in-the-fight-against-cancer https://www.hastim.fr/en/publications/hastim-articles https://www.hastim.fr/en/publications/human-health https://www.hastim.fr/en/publications/aminal-health https://www.hastim.fr/en/publications/case-report https://www.hastim.fr/en/publications/newsletter https://www.hastim.fr/en/publication/case-report-canine-intestinal-mucinous-carcinoma-and-immunotherapy https://www.hastim.fr/en/publication/apavac-immunotherapy-integrated-into-a-multimodal-strategy-for-the-treatment-of-canine-osteosarcoma https://www.hastim.fr/en/publication/case-report-efficacity-of-apavac-immunotherapy-in-the-adjuvant-treatment-of-canine-mucosal-melanoma https://www.hastim.fr/en/publication/the-3-keys-to-autologous-immunotherapy-apavac-3-hydroxyapatite https://www.hastim.fr/en/publication/the-3-keys-to-autologous-immunotherapy-apavac-2-heat-shock-proteins https://www.hastim.fr/en/publication/the-3-keys-to-autologous-immunotherapy-apavac-1-tumor-antigens https://www.hastim.fr/en/publication/autologous-therapeutic-vaccine-apavac-lymph-node-system-role https://www.hastim.fr/en/publication/apavac-autologous-therapeutic-vaccine-and-tp53-gene https://www.hastim.fr/en/publication/case-report-equine-melanoma https://www.hastim.fr/en/publication/apavac-autologous-vaccine-which-indications-for-which-animals https://www.hastim.fr/en/publication/case-report-canin-osteosarcoma https://www.hastim.fr/en/publication/how-to-preparer-autologous-anti-tumor-vaccine https://www.hastim.fr/publication/genomic-landscape-fr https://www.hastim.fr/publication/a-pilot-study-with-a-therapeutic-vaccine-based-on-hydroxyapatite-ceramic-particles-and-self-antigens-in-cancer-patients https://www.hastim.fr/publication/immunotherapie-active-chez-les-chiens-atteints-de-lymphome-a-cellules-b-une-experience-de-5-ans-dans-deux-centres-doncologie https://www.hastim.fr/en/animal-health/apavac-kit/the-advantages-of-apavac-treatment https://www.hastim.fr/en/animal-health/apavac-kit/preparing-for-apavac-treatment https://www.hastim.fr/en/animal-health/diseases-treated/the-species-concerned https://www.hastim.fr/en/animal-health/diseases-treated/pets https://www.hastim.fr/en/animal-health/diseases-treated/a-therapeutic-strategy https://www.hastim.fr/sante-animale/pathologies-traitees/une-strategie-therapeutique https://www.hastim.fr/en/publication/transfection https://www.hastim.fr/en/human-health/human-oncology-objective/background-and-concepts https://www.hastim.fr/en/human-health/human-oncology-objective/preliminary-results https://www.hastim.fr/en/human-health/human-oncology-objective/our-goal https://www.hastim.fr/en/publication/genomic-landscape-en https://www.hastim.fr/en/publication/a-pilot-study-with-a-therapeutic-vaccine-based-on-hydroxyapatite-ceramic-particles-and-self-antigens-in-cancer-patients https://www.hastim.fr/en/publication/active-immunotherapy-in-dogs-with-b-cell-lymphoma-a-5-year-experience-in-two-oncolgy-centers https://www.hastim.fr/sante-animale/pathologies-traitees/les-animaux-de-compagnie https://www.hastim.fr/trk-organization_guest_main-feed-card-text https://www.hastim.fr/en/immunotherapy-in-the-fight-against-cancer https://www.hastim.fr/en/preparing-for-apavac-treatment https://www.hastim.fr/en/publication/enhanced-therapeutic-effect-of-apavac-immunotherapy-in-combination-with-dose-intense-chemotherapy-in-dogs-with-advanced-indolent-b-cell-lymphoma https://www.hastim.fr/en/publication/la-gazette-du-midi-december-2022 https://www.hastim.fr/en/publication/multimodal-management-including-immunotherapy-form-multicentric-squamous-cell-carcinoma https://www.hastim.fr/en/the-advantages-of-apavac-treatment https://www.hastim.fr/en/veterinarians https://www.hastim.fr/la-preparation-du-traitement-apavac https://www.hastim.fr/les-atouts-du-traitement-apavac https://www.hastim.fr/limmunotherapie-pour-lutter-contre-le-cancer https://www.hastim.fr/publication/enhanced-therapeutic-effect-of-apavac-immunotherapy-in-combination-with-dose-intense-chemotherapy-in-dogs-with-advanced-indolent-b-cell-lymphoma https://www.hastim.fr/publication/la-gazette-du-midi-decembre-2022 https://www.hastim.fr/publication/opportunities-and-challenges-of-active-immunotherapy-in-dogs-with-b-cell-lymphoma-a-5-year-experience-in-two-veterinary-oncology-centers https://www.hastim.fr/publication/prise-en-charge-multimodale-dun-carcinome-epidermoide-multicentrique-incluant-limmunotherapie https://www.hastim.fr/sante-animale/traitement-du-cancer/limmunotherapie-pour-lutter-contre-le-cancer https://www.hastim.fr/un-traitement-a-faible-impact-environnemental https://www.hastim.fr/veterinaires